Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 854.5 JPY -0.4%
Market Cap: 674.2B JPY
Have any thoughts about
Rohto Pharmaceutical Co Ltd?
Write Note

Rohto Pharmaceutical Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Rohto Pharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Rohto Pharmaceutical Co Ltd
TSE:4527
Other Long-Term Assets
ÂĄ8.9B
CAGR 3-Years
-4%
CAGR 5-Years
12%
CAGR 10-Years
7%
Shiseido Co Ltd
TSE:4911
Other Long-Term Assets
ÂĄ71.7B
CAGR 3-Years
-14%
CAGR 5-Years
-8%
CAGR 10-Years
0%
Kao Corp
TSE:4452
Other Long-Term Assets
ÂĄ65.9B
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Kose Corp
TSE:4922
Other Long-Term Assets
ÂĄ24.7B
CAGR 3-Years
28%
CAGR 5-Years
20%
CAGR 10-Years
11%
F
Fancl Corp
TSE:4921
Other Long-Term Assets
ÂĄ3.6B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Other Long-Term Assets
ÂĄ4B
CAGR 3-Years
15%
CAGR 5-Years
-4%
CAGR 10-Years
6%
No Stocks Found

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
651.2B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
3 201.93 JPY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Rohto Pharmaceutical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
8.9B JPY

Based on the financial report for Sep 30, 2024, Rohto Pharmaceutical Co Ltd's Other Long-Term Assets amounts to 8.9B JPY.

What is Rohto Pharmaceutical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
7%

Over the last year, the Other Long-Term Assets growth was -3%. The average annual Other Long-Term Assets growth rates for Rohto Pharmaceutical Co Ltd have been -4% over the past three years , 12% over the past five years , and 7% over the past ten years .

Back to Top